To characterize the pharmacokinetics of the dual 5a-reductase inhibitor GI198745 (dutasteride) to allow for more accurate predictions of GI198745 concentrations after different dosing schedules. Methods In this randomized, single-blind, parallel group study, 32 healthy male volunteers received single oral doses of GI198745 ranging from 0.01 to 40 mg. Data were analysed by nonlinear mixed effects modelling using NONMEM where both linear and nonlinear pharmacokinetic models were examined. Results The time course of GI198745 serum concentrations indicated concentration dependent elimination, with the apparent half-life increasing with dose. Data were best described by a two-compartment model with first order absorption and parallel linear and nonlinear elimination pathways. Drug absorption was rapid, and was followed by a short distribution phase. A high volume of distribution (511 l) and a low linear clearance (0.58 l h −1 ) combined to give a half-life of up to 5 (1-7) weeks at high concentrations. As concentrations declined towards K m (0.96 ng ml −1 ), the proportion eliminated by the relatively rapid saturable elimination pathway, with a maximum clearance of 6.2 l h −1 , increased and the half-life reduced to about 3 days. The estimated inter individual variability for the linear clearance was high (CV=70%). Conclusions GI198745 pharmacokinetics are well described by a pharmacokinetic model with parallel linear and nonlinear elimination. Simulations using this model show that at daily doses of 0.1 mg the steady state drug concentrations, and the rate at which these are achieved, are mainly influenced by the nonlinear pathway, while at daily doses above 1 mg they are almost entirely influenced by the linear pathway.
Introduction
are not yet fully understood, the type 2 5a-reductase is the primary isozyme present in human prostate [3] . Pharmacological intervention to treat benign prostatic hyperplasia (BPH) is desirable due to the high incidence Treatment of patients with finasteride, a selective type 2 5a-reductase inhibitor, reduces circulating DHT concen-of this disease and its resulting erosion in the quality of life for affected men. Approximately 40-50% of men trations to 20-40% of baseline values and has proven efficacious for the treatment of BPH [4] . There is a over the age of 60 years suffer symptoms of bladder outlet obstruction caused by BPH and ultimately 25-30% possibility that lowering circulating DHT concentrations beyond those observed with finasteride may lead to faster of these require surgery [1, 2] . Dihydrotestosterone (DHT) is thought to be the androgen primarily responsible onset of action and/or greater magnitude of clinical effect in the treatment of symptoms associated with BPH. for the development of BPH. Testosterone is converted to DHT by 5a-reductase of which there are two types. GI198745 (17b-N (2,5-bis (trifluormethyl)phenylcarbamoyl)-4-aza-5-androst-1-en-3-one) is a potent and [5] . In rats and dogs, GI198745 appears more potent Data analysis than finasteride, a result which likely reflects the greater inherent potency [5] and a longer terminal half-As the expected half-life of GI198745, and thus the duration of the sampling period, was long, the study was life [6] .
Here we report pharmacokinetic modelling of by necessity of a parallel group design. This presents special problems for the analysis of the data, as data from GI198745 using data from the first human single dose escalation study. different individuals will have to be combined to describe the full dose range. A valid way of combining data from different individuals is using mixed effects modelling,
Methods
where both population average model parameters and the associated inter individual variabilites are estimated.
Study design
Therefore, all analyses were carried out using a nonlinear This study was part of a randomized, single-blind, placebo mixed-effect model. The data analysis was performed controlled, parallel group study in which 48 healthy using the first-order method. Data analysis and simulations males, aged 20-57 years (median 37 years) and weighing were performed using NONMEM IV, level 1. As can be seen from Figure 1 , the terminal half-life of received doses of 0.01, 0.1, 1, 2.5, 5, 10, 20 and 40 mg.
GI198745 apparently increased with dose. The AUC GI198745 was administered as oral solutions in a volume increased nonlinearly with dose while C max apparently of 7.5 ml of PEG400/TWEEN80 0.01% except for remained proportional to dose. Three different models 40 mg which was administered in 15 ml. The doses were were applied to the data: administered together with 240 ml of water.
1 A two compartment model with first order absorption Intake of any medications was prohibited from 1 week and an absorption lag-time. prior to dosing. Alcoholic beverages, caffeine containing 2 As model (1) but with Michaelis-Menten type food or beverages and all tobacco products were saturable elimination. prohibited from 24 h prior to drug administration. The 3 As model (1) but with two parallel elimination subjects were fasted from 8 h prior to dosing until 4 h pathways, one saturable and one nonsaturable. This model post dosing.
can be described using a system of differential equations: Blood samples (5 ml) for assay of GI198745 levels were drawn predose and at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 h dA 1 dt =−k a A 1 (1) and 2, 3, 7, 14, 21, 28 and, for three subjects, 56 days after dosing. The actual time of sampling was recorded and used in all calculations.
Samples were allowed to stand and clot for at least 30 min and were then centrifuged at a minimum of (2) 3000 g for 15 min. Serum was harvested and stored at −70°C.
GI198745 levels were analysed by a LC/MS assay with dA 3 dt =k 23 A 2 −k 32 A 3 (3) a quantification limit of 0.1 ng ml −1 [7]. The assay displayed an intraday coefficient of variation of <15% at where t represents time, A 1 , A 2 and A 3 are the amounts the limit of quantification and ≤10% over the rest of the in the absorption, central and peripheral compartments, concentration range. The interday coefficient of variation respectively, k a is the absorption rate constant, V c is the was <10% across the concentration range. All doses volume of the central compartment, K m is except 0.01 mg gave detectable levels and all available the concentration at which the saturable pathway operates data were included in the analysis.
at half the maximal rate, V max is the maximum elimination rate of the saturable pathway, k 20 is the linear elimination rate constant and k 23 and k 32 are intercompartmental rate ith subject, P the average population parameter value and g i the deviation for an individual from the population constants.
For all models, k 23 , k 32 and k 20 were reparameterised mean. g i is assumed to be normally distributed with mean zero and a variance to be estimated. to more physiologically relevant parameters as follows:
The residual variability (e), corresponds to the deviation k 32 =Q/V p (5) of observed serum concentrations from the curve prek 20 =CL l /V c (6) dicted by the subject specific parameters (P i ). e is assumed to be normally distributed with mean zero. The variance where Q is the intercompartmental clearance, CL l is the linear, nonconcentration dependent, clearance and V p is of e will be estimated in the analysis. e was included in the model using the following equation: the volume of the peripheral compartment. V ss , the volume of distribution at steady state, is the sum of V c C=Ĉ (1+e) (8) and V p . This model was examined with and without an absorption lag-time.
where C is the measured serum GI198745 concentration and Ĉ is the value predicted by the model using the As GI198745 was administered orally, volumes and clearances in the above model are not absolute values, individual parameters. The model was evaluated with interindividual varia-and it is assumed that the bioavailability of GI198745 is independent of the administered dose.
bilities initially applied to all parameters. If the interindividual variability for a parameter approached zero it was not included in the model.
Variability model
As this study was performed in a relatively small group of healthy volunteers, no attempts were made to examine Interindividual variability in the pharmacokinetic parameters was included in the model as described in eqn 7, the effects of covariates on the pharmacokinetic parameters. where P i is the pharmacokinetic parameter value for the
Simulations
The population estimates of the parameters were used to calculate the contributions of nonlinear and linear clearance to total clearance for a range of concentrations. Simulations of dosing to steady state were performed using population parameters and the time to achieve steady state was calculated from the simulated concentrations.
For the final model, individual predicted parameters from all subjects that had received doses of at least 2.5 mg were obtained using a Bayesian approach (POSTHOC routine of NONMEM). Data from these individuals were used as only individuals at these high doses could be expected to have data supporting all parts of the model. The parameters from these subjects were used to simulate dosing regimens, with the purpose of illustrating the interindividual variability in kinetics and comparing the consequences of different loading and maintenance dosing the proportion eliminated by the relatively rapid saturable elimination pathway, with a maximum clearance of 6.2 regimens over a range of dose levels.
l h −1 (calculated as V max /K m ), increased and the half-life reduced to about 3 days. The population parameters were Results used to calculate the dependence of the linear, nonlinear and total clearance on the GI198745 concentration, as The linear two compartment model could not describe the pharmacokinetics of GI198745 accurately. Individual shown in Figure 3 . At low concentrations (below 0.1 ng ml −1 ) the nonlinear pathway is not saturated and predicted values did not follow the shape of the measured profiles and there were clear dose dependent trends.
clearance is approximately independent of concentration. At concentrations over 0.1 ng ml −1 the nonlinear clear-Using the two compartment Michaelis-Menten model the shape of the individual curves improved in some ance starts to become saturated and clearance is highly dependent of concentration. When concentrations exceed cases, but the overall fit to the data was not improved as indicated by trends in the residuals and by an increase in 10 ng ml −1 , the slower linear clearance dominates, and the total clearance is again concentration independent. the objective function by 11.8.
Using the model with one linear and one nonlinear The pharmacokinetic parameters were generally well estimated, with the standard error for the estimation pathway substantially improved the fit both in terms of patterns in the residuals and in a drop in the objective being around 10-30% of the estimated population parameter values, except for V max (39%) and K m (49%). function by 64.0, which indicated that the model was statistically significantly better than both the linear and These two parameters were highly correlated, and reparameterising the model to include the ratio V max /K m Michaelis-Menten models. There was good agreement between actual and predicted concentrations, and there showed that this could be well estimated (s.e. mean= 14%). were no obvious trends in the weighted residuals vs time. There was no apparent dependence of weighted residuals
The interindividual variability associated with the pharmacokinetic parameters was generally high, especially on the predicted concentrations indicating that the applied residual variance model was appropriate. Individually for the linear clearance parameter (CV=69%), the intercompartmental clearance (62%) and the absorption predicted values closely followed the observed concentrations ( Figure 2) . rate constant (70%). The residual variability was lower at 13%. The variability was well determined except for that The parameters of the final model are displayed in Table 1 . After a short lag-time, the absorption of associated with k a (s.e. mean=77%) and t lag (53%). The simulations of dosing to steady state showed the GI198745 was rapid, followed by a brief distribution phase. The pharmacokinetics of GI198745 showed an time to achieve steady state to be dose dependent, ranging from about 1 week at 0.01 mg day −1 to 3 months at unusual profile, where a high volume of distribution (511 l) and a low linear clearance (0.58 l h −1 ) combined doses greater than 0.5 mg day −1 . The rate of approach to steady state is independent of dose at doses over to give a half-life of up to 5 weeks at high concentrations. As concentrations declined towards K m (0.96 ng ml −1 ) 0.5 mg day −1 (Figure 4 ). 
Discussion
In the present study, a low serum clearance and a high volume of distribution was observed. This agrees with the pharmacokinetics observed after intravenous doses in animals [6] . As no intravenous dose has been given to man, the bioavailability of GI198745 is unknown, and the modelling was performed assuming that the bioavailability was independent of dose. In animal studies, the bioavailability has been reported as 43% in dogs and 100% in rats [6] . Across the doses administered in the present study C max appears to increase proportionally to dose, indicating that absorption is linear, furthermore, opposite of what was observed here. Possible explanations for the nonlinearity include a low Individual predicted parameters from the 20 subjects who received doses of at least 2.5 mg were used to capacity metabolic pathway or saturable biliary excretion. Another possible explanation for the nonlinearity could simulate GI198745 time-concentration profiles after different dosing schedules, as exemplified in Figure 5 .
be irreversible binding of GI198745-5a-reductase and subsequent breakdown, a process that would be saturated low precision in the estimation of the variability of some of the pharmacokinetic variables is likely due to the small as the amount of free 5a-reductase decreases.
The close agreement between actual and individually sample size. Using the variability of CL l (69%) which was relatively well estimated from these data, steady state predicted concentrations ( Figure 2) indicates that individual predictions from this model, at least in this data rich levels could be expected to have high variability.
In summary, this paper has demonstrated that the situation, would be appropriate for use in pharmacokinetic/pharmacodynamic modelling.
pharmacokinetics of GI198745 are well described by a model using parallel linear and nonlinear elimination. In Even though a major nonlinearity exists in the elimination of GI198745, the presence of a linear spite of the dominance of the nonlinear pathway at low concentrations, at daily doses above 1 mg day −1 the elimination pathway ensures that unlimited accumulation will not take place. Simulations showed that for doses steady state concentrations are almost entirely dependent on the linear clearance mechanism. ≥1.5 mg day −1 the nonlinear pathway will contribute less than 10% of the elimination of GI198745 at steady state. Thus at these doses the nonlinear pathway is of little importance in defining the steady state level. As can References be expected from the long half-life at higher concentrations, up to 3 months of dosing are needed to reach
